Drug Profile


Alternative Names: BF-derm 1

Latest Information Update: 20 Aug 2015

Price : $50

At a glance

  • Originator Biofrontera AG
  • Class Skin disorder therapies
  • Mechanism of Action Histidine decarboxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Urticaria

Highest Development Phases

  • Phase II Urticaria

Most Recent Events

  • 20 Aug 2015 BF-derm1 is still in phase-II development for Urticaria in Europe
  • 27 Jul 2009 Efficacy and adverse events data from a phase II trial in Urticaria released by Biofrontera
  • 27 Jul 2009 BF-derm1 is available for licensing (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top